This prospective study seeks to evaluate the impact of the uptake period (time between radiotracer injection and imaging) on the SUVmax using 18F-DCFPyL in PSMA PET/CT in the primary diagnosis of localised clinically significant prostate cancer. Here, FOLH1 is linked to prostate cancer.